Saisheng Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company at negative 144 million yuan, swinging from profit to loss. Total operating revenue was 181 million yuan, down 8.17% from the same period last year. Net cash inflow from operating activities was 11.4043 million yuan, down 61.13% year on year. The company's latest asset-liability ratio was 3.90%, gross margin was 67.84%, and ROE was negative 4.47%. Diluted earnings per share were negative 0.30 yuan, down 400.00% from the same period last year.
Beijing Science Sun Pharmaceutical Co LtdCompany reported a net loss of 144 million yuan, swinging from profit to loss, with revenue down 8.17%.
